Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer

Maki Nagase, Nobuharu Ohshima, Masahiro Kawashima, Masahiro Ohgiya, Miki Ikeda, Yoshiteru Morio and Atsuhisa Tamura

Abstract:
Molecular-targeted drugs (MTDs), such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase inhibitors, are used to treat non-small-cell lung cancer (NSCLC). The incidence of rash caused by EGFR-TKIs and discontinuation of MTDs because of rash are issues. Rapid desensitization therapy (RDT) was performed in five patients who developed severe rash after introduction of MTDs and was successful in four, all of whom showed no rash relapse. RDT may thus be useful for treating rash in patients receiving MTDs for NSCLC.

Key words: rapid desensitization therapy, EGFR-TKI, ALK inhibitor, NSCLC

Introduction
Since 2000, a number of new drugs, such as molecular-targeted drugs (MTDs) and immune checkpoint inhibitors, have been developed and are now being used in the treatment of non-small-cell lung cancer (NSCLC). MTDs that target driver genes required for the development and growth of cancers are currently approved in Japan for epidermal growth factor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, ROS1 gene translocations, and kinase inhibitors of BRAF gene mutations. The current guidelines in Japan recommend the use of these kinase inhibitors in the first-line treatment of patients positive for these driver gene mutations and translocations. However, many patients experience side effects, and the treatment must be discontinued before it can be effective.

Specific adverse reactions to MTDs include rash, periangual inflammation, and diarrhea. The rate of rash is high. A survey of the specific drug use of erlotinib found that some patients had difficulty continuing treatment because of a rash and that the rate of discontinuation was as high as 8.75% (1).

Case Report

Patients
Five patients (1 man, 4 women; average age 64 years old, age range 43-75 years old) whose treatment had been discontinued because of the appearance of severe rash after primary treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or an ALK inhibitor (ALKi) from January 2016 to August 2017 underwent RDT (Table 1). Four patients received an EGFR-TKI, and one received an ALKi. In addition, since the rash had appeared at the initial dose in EGFR-TKI administration, administration was attempted with a decreased dose; however, as the rash became exacerbated after this attempt, the administration...
was discontinued altogether. All rashes were classified as G3 according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0) (6). The median period from the drug administration to the appearance of the rash was 36 days. The rash extended to the face, neck, trunk, and extremities.

All patients provided their written, informed consent. This study was reviewed and approved by the ethics committee of the National Hospital Organization, Tokyo National Hospital, and was conducted according to the principles expressed in the Declaration of Helsinki.

**RDT**

Fexofenadine 60 mg, levocetirizine 5 mg, and nizatidine 150 mg were administered on the day before RDT. Fexofenadine 120 mg, levocetirizine 5 mg, and nizatidine 150 mg were administered 1 hour before RDT. The target drug was then started as a dose of 0.02 mg (target dose 100 mg) or 0.075 mg (target dose 600 mg), increased every 15 minutes, and then administered at the daily dose shown in Tables 2 and 3. The target dose in the erlotinib group was reduced to the usual dose (Table 1, 2). The reason for reducing the target dose in the erlotinib group was that the rash did not improve even after the dose was reduced in order to attempt continued administration.

**Evaluations**

Success with RDT was defined as treatment continuation without exacerbation of the rash. Each patient’s rash was graded according to the CTCAE (version 4.0) (6).

**Case Series**

In Patient 1, the right upper lobe primary lesion decreased in diameter from 40 to 35 mm after erlotinib administration, and the right cancerous pleural effusion also showed a resolving tendency. However, the right pleural effusion tended to increase after erlotinib discontinuation. In Patient 2, erlotinib was administered, and the primary lesion in the left lower lobe was 32 mm in diameter and remained unchanged. In Patient 3, erlotinib administration reduced the diameter of the primary lesion in the right middle lobe from 17 to 12 mm. In Patient 4, meningeal dissemination tended to decrease with erlotinib administration. In Patient 5, the primary lesion in the right middle lobe decreased in diameter from 34 to 16 mm after the administration of alectinib.

All patients were successfully treated with an EGFR-TKI or ALKi. A moisturizer and topical application of a steroid preparation were used as the treatment for the rashes in all

---

**Table 1. Characteristics of the Five Patients.**

| Patient | Age (y) | Sex | Stage | Drug used (mg) | Dose at the time of discontinuation (mg) | Time from drug initiation to discontinuation (days) | Rash severity | Rash type | Target dose at the time of RDT (mg) | Max eosinophil count during appearance of rash (per L) | Period from discontinuation to RDT (days) | Eosinophil count prior to RDT (per L) | Eosinophil count after RDT (per L) | Ratio of the eosinophil count after to before RDT. | Course |
|---------|---------|-----|-------|---------------|------------------------------------------|-------------------------------------------------|--------------|-----------|------------------------------------|------------------------------------------|------------------------------------------|-------------------|--------------|-----------------------------|--------|
| 1       | 75      | M   | Stage IV | Erlotinib 150 | Erlotinib 100                            | 14                                              | G3           | Punctate  | Erlotinib 100                       | 158                                      | 27                                                      | 221                             | 300                           | 1.35                                      | Continued |
| 2       | 69      | F   | Stage IV | Erlotinib 150 | Erlotinib 100                            | 36                                              | G3           | Face, occiput, and neck             | 3,288                                     | 40                                                      | 364                             | 637                           | 1.75                                      | Unable to continue |
| 3       | 70      | F   | Stage IV | Erlotinib 150 | Erlotinib 100                            | 44                                              | G3           | Abdomen, back, and limb             | 413                                       | 23                                                      | 119                             | 448                           | 3.76                                      | Continued |
| 4       | 63      | F   | Stage IIIA| Erlotinib 150| Erlotinib 100                            | 288                                             | G3           | Neck, trunk, and limbs              | 308                                       | 32                                                      | 208                             | 318                           | 1.52                                      | Continued |
| 5       | 43      | F   | Stage IV | Alectinib 600 | Alectinib 600                            | 26                                               | Not listed | Face, neck, trunk, and limb         | 363                                       | 17                                                      | 172                             | 353                           | 2.05                                      | Continued |

MINO: minocycline hydrochloride, SG: strongest topical steroids, VS: very strong topical steroids, M: moderate topical steroids.
patients. Systemic minocycline was also given to two patients who continued this prescription during their treatment. After RDT, the rash improved to G1 in two of five patients and improved to an unknown grade in three patients (Table 1).

Four of the five patients who underwent RDT were able to continue MTD treatment without developing a rash (Table 1). Three of the four patients who received an EGFR-TKI and the one patient who received an ALKi were treated successfully. One of the five patients was unable to continue treatment due to a severe rash (grade 3) on day 8 of RDT that made it difficult to continue.

A comparison of eosinophil counts before the start of RDT showed that the 4 patients who were able to continue MTD treatment had a low eosinophil count of 119-221/μL, whereas the 1 patient who was unable to continue MTD treatment had a higher count of 364/μL. There was no characteristic trend in the change in the eosinophil count from before to after rechallenge in the patients who were or were not able to continue MTD treatment.

Patient 5 was a 43-year-old woman with lung adenocarcinoma, cT4N3M1b stage IV, multiple brain metastases other than the primary lesion, left parietal bone metastases, and multiple metastases in both lungs (Figure). Because the primary lesion was 34 mm and was positive for ALK gene translocation, treatment with alectinib 600 mg was started. However, a grade 3 rash appeared on day 24 of administration, and alectinib was discontinued on day 26. RDT with alectinib was performed on day 42 after initiation. On day 77 after initiation, the lung metastatic lesion became smaller, and the primary lesion shrunk to 26 mm (Figure). On day 105 after initiation, resolution of brain and bone metastases was observed. We confirmed that alectinib administration could be continued without relapse of the rash after day 105 and that the primary lesion had decreased to 7 mm at day 991 from the start. The rash was not exacerbated by RDT, and this patient was able to continue alectinib treatment over a long period. The treatment was considered to have been successful in this patient.

### Discussion

In many facilities, the usual desensitization therapy in which the treatment is started with a small MTD dose followed by a gradual increase is adopted. However, its disadvantage is that it takes time to increase the drug dose. In the case of lung cancer patients, RDT seemed to be useful, since it can shorten the withdrawal period without any concerns about the pathogenic progression of the cancer and allows for the required dose to be rapidly reached. In addition, it seemed meaningful in preventing anxiety among patients due to drug withdrawal, since whether or not to readminister the drug can be determined after only a few days.

In this study, retreatment with MTDs was possible after RDT in four of the five patients. These findings suggest that RDT may be useful when restarting MTD treatment in patients who had to discontinue treatment because of a rash. RDT required only a few days, and it was possible to restart MTD promptly (an average of 24 days after discontinuation) because the side effects were treated successfully. RDT may facilitate the quick restart of a therapeutic drug by reducing the treatment-free period so that the treatment can be restarted quickly in patients who had to discontinue treatment because of serious side effects.

Erlotinib RDT was successful in three out of four patients, and alectinib RDT was successful in one patient. The target dose in the erlotinib-treated patients with RDT was reduced compared with the initial dose. This was because the rash appeared at the initial administration, and we initially attempted to continue the administration by reducing the dose; however, the rash appeared even with the reduced dosage. In the present cases, RDT was performed by dosing

| Table 2. Erlotinib Rapid-desensitization-therapy Protocol (target 100 Mg/day). |
|---|
| Day | Time | Erlotinib dose |
| Day 1 | 10:00 | 0.02 mg |
| | 10:15 | 0.05 mg |
| | 10:30 | 0.1 mg |
| | 10:45 | 0.2 mg |
| | 11:00 | 0.4 mg |
| | 11:15 | 0.78 mg |
| | 11:30 | 1.56 mg |
| | 11:45 | 3.12 mg |
| | 12:00 | 6.25 mg |
| | 12:15 | 12.5 mg |
| | 12:30 | 25 mg |
| | 12:45 | 50 mg |
| Day 2 | | 50 mg twice a day |
| Day 3 | | 100 mg once a day |

| Table 3. Alectinib Rapid-desensitization-therapy Protocol (target 600 Mg/day). |
|---|
| Day | Time | Alectinib dose |
| Day 1 | 10:00 | 0.075 mg |
| | 10:15 | 0.15 mg |
| | 10:30 | 0.3 mg |
| | 10:45 | 0.6 mg |
| | 11:00 | 1.2 mg |
| | 11:15 | 2.4 mg |
| | 11:30 | 4.8 mg |
| | 11:45 | 9.6 mg |
| | 12:00 | 19.2 mg |
| | 12:15 | 38.4 mg |
| | 12:30 | 76.8 mg |
| | 12:45 | 153.6 mg |
| | 24:45 | 300 mg |
| Day 2 | | 300 mg twice a day |
just before the rash appearance. This is the reason why RDT was successful when dose reduction was not. Patients who were unable to restart treatment had a high peripheral-blood eosinophil count of 3,288/μL when the rash appeared during the initial treatment; this was much higher than the range in patients who were able to restart treatment (158-413/μL). The eosinophil count in peripheral blood before RDT was also high when the treatment could not be restarted.

The EGFR is present in the epithelial cells of tumor cells and the normal skin. This receptor binds to ligands, such as EGF, and stimulates the growth, metastasis, and angiogenesis of tumor cells. EGFR-TKIs inhibit EGFR tyrosine kinase activity, thereby inhibiting the EGFR function. In normal skin, the EGFR controls the proliferation and differentiation of keratinocytes. Inhibition of the EGFR by an EGFR-TKI stops keratinocyte proliferation and induces apoptosis, which causes thinning of the entire epidermis and leads to dyskeratosis, thinning of keratinization, and abnormal differentiation of the nail mother cells. All of these processes are thought to contribute to skin disorders, such as the rash associated with EGFR-TKI treatment (7, 8). The mechanism responsible for the rash caused by EGFR-TKIs and ALKi seems to differ from that of allergic reactions, as mentioned above, the present results suggest that RDT to prevent skin rash caused by MTDs may be beneficial for drug reintroduction and that allergic factors may also contribute to the skin rash caused by MTDs. One study of RDT suggested that the repeated administration of increasing allergen doses in a short time may lead to exhaustion of storage mediators due to the repeated stimulation and release (10). Exhaustion of storage mediators exacerbates allergic reactions, which may have led to the high success rate in this study.

Our study had a small sample size of only five patients, and our observations will need to be confirmed in a larger study. We were unable to investigate the changes in immunoglobulin levels in this patient group; these changes should also be evaluated in future studies.
Our findings provide novel evidence about the potential usefulness of RDT for preventing rash in patients being treated with erlotinib and alectinib. In addition, this approach may be applicable to other TKIs, such as Osimertinib and Afatinib. RDT may be effective in patients requiring the reintroduction of treatment that had to be discontinued because of the side effect of rash.

The authors state that they have no Conflict of Interest (COI).

References

1. Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLAR-STAR). J Thorac Oncol 7: 1296-1303, 2012.
2. Gomez R, Harter P, Lück HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19: 1284-1287, 2009.
3. Sasaki Y, Kurashima A, Morimoto K, et al. Experience of rapid drug desensitization therapy in the treatment of mycobacterial disease. Kekkaku 89: 797-802, 2014 (in Japanese).
4. Awad MM, Lax TF, Slawski BR, Shaw AT. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol 9: 1726-1728, 2014.
5. Ban GY, Jeong YJ, Lee SH, et al. Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. Respir Med 147: 44-50, 2019.
6. U.S. Department of Health and Human Services, Common Terminology Criteria for Adverse Events v4.0. U.S. Department of Health and Human Services, Washington, DC, USA, 2010.
7. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6: 803-812, 2006.
8. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol 46: 291-298, 2016.
9. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol 41: 1004-1013, 2011.
10. Maintz L, Bussmann C, Bieber T, Novak N. Contribution of histamine metabolism to tachyphylaxis during the buildup phase of rush immunotherapy. J Allergy Clin Immunol 123: 701-703, 2009.

The Japanese Society of Internal Medicine

Intern Med Advance Publication

© The Japanese Society of Internal Medicine